GEN-MKT-18-7897-A
Oct 11, 2017 | Blogs, Technology | 0 comments
If you are working with complex assays that demand exceptionally selective quantitative and qualitative performance, sometimes even the most powerful LC-MS/MS technology can’t always cut it alone.
Perhaps you are struggling to separate isobaric species, isolate challenging co-eluting analytes or reduce high background noise? Regardless of your challenge, the outcome is the same. You probably aren’t getting the levels of quantitation or characterization you need, so method development has become cumbersome, and workflow performance is suffering.
Now you can bring a new dimension of selectivity to your LC-MS/MS analysis on select SCIEX Triple Quad™, QTRAP® and TripleTOF® Systems with SelexION® Differential Mobility Separation (DMS) Technology. The SelexION DMS cell:
Harness the power of differential mobility separations to simplify your sample preparations, while achieving unprecedented levels of selectivity. Find out more by downloading the SelexION brochure.
How does it work?Gas phase differential mobility separation within the SelexION device planar mobility cell is based on the ion’s size and shape, and the difference between their unique differential mobilities across high and low energy fields. Gas phase separation occurs prior to entering the mass analyzer where the compounds are then further separated by m/z ratios.
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network